Exosomes for mRNA Delivery
In recent, exosomes secreted by a variety of cell types have emerged as promising carriers for mRNA-based therapeutics. These vesicles are biocompatible, commonly measure 40~150 nm in diameter. Remarkably, their intrinsic expression of transmembrane and membrane-anchored proteins facilitates tissue-directed delivery as well as the cellular uptake of encapsulated exosomal contents. To promote the application of exosomes as carriers for therapeutically related mRNA delivery, Creative Biogene are committed to offering a series of exosome-related services, including exosome isolation, identification, labeling, manufacturing, and production of mRNA-encapsulating exosomes.
Exosomes as ideal delivery systems for nucleic acid therapy
Based on their natural properties, exosomes have significant advantages as ideal delivery systems for nucleic acid therapy. There are several major reasons, including,
- As naturally transported nanovesicles, exosomes can be secreted by a variety of cell types.
- Exosomes are able to penetrate multiple biological barriers (such as the blood-brain barrier) due to their cell surface compounds.
- Exosomes can directly stimulate target cells and transfer membrane receptors between cells, therefore avoiding diffusion into tissues by phagocytes/ monocytes.
- Compared to synthetic delivery carriers, exosomes have excellent stability and lower cytotoxicity in vivo.
Exosome-mediated mRNA delivery for personalized medicine
The recent advance in exosome technologies has greatly promoted the use of exosome-based mRNA delivery systems in the treatment of various diseases, such as breast cancers, Parkinson's disease, glioma, and leukemia. For example, since their immunogenicity is relatively low, exosomes are utilized to deliver mRNA encoding HChrR6 for the treatment of HER2+ breast cancer. HChrR6 is a bacterial enzyme and has the capability to convert the prodrug (CNOB) into the drug (MCHB) in the tumors. The HChrR6 mRNA-encapsulating exosomes were generated by transfection of cells with XPort/HChrR6 coding plasmid, and can specifically kill HER2+ cells by targeting the HER2 receptor (EXO-DEPTs), leading to significant growth arrest of breast cancer in mice. In addition, the most crucial reason for Parkinson's disease is neuronal cell death. The catalase-delivery is believed as an effective therapeutic approach to protect the neurons from oxidative damage. Using a set of EXOsomal transfer into cells (EXOtic) devices, researchers produced catalase mRNA-encapsulating exosomes and delivered them to the brain. This therapeutic modality had been reported to attenuate neuroinflammation in models with Parkinson's disease in vitro and in vivo.
Exosome-mediated mRNA delivery for personalized medicine. (Aslan, C.,et al, 2021)
To use exosomes as a drug delivery system, first, a sufficient quantity of exosomes must be obtained. And the exosomes must be pure enough to be free of cellular and molecular contamination. Additionally, to introduce the exosomes' function, their composition and cargo are necessary to be carefully characterized. Here, we are offering a series of exosome related services for mRNA delivery, including,
- Exosome isolation and purification services
- Exosome identification and analysis services
- Exosome labeling and tracking services
- Exosome manufacturing services
- mRNA-encapsulating exosome production
Creative Biogene is a leading service provider in mRNA-based drug research and development (R&D). Besides a series of advanced techniques for IVT mRNA delivery, we also offer various mRNA delivery systems, including exosomes, one of the promising carriers. In addition to the scalable upstream production and isolation of exosomes, we also provide downstream processing for efficient purification, characterization, and labeling, to obtain high-quality, functional exosomes that are ready to use for mRNA delivery. If you have any questions about our service, please don't hesitate to contact us and we will spare no effort to answer them for you.
- Aslan, C.,et al. (2021). "Exosomes for mRNA delivery: a novel biotherapeutic strategy with hurdles and hope." BMC biotechnology, 21(1), 1-12.